Read on Twitter
DRDO says an anti-COVID-19 therapeutic application of drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine & Allied Sciences in collaboration with Dr Reddy’s Labs. Clinical trial results show this molecule helps in faster recovery of hospitalized patients
Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID in the ongoing pandemic: DRDO
The drug, which comes in powder form in sachet & is taken orally by dissolving in water, accumulates in virus infected cells & prevents virus growth by stopping viral synthesis & energy production. Its selective accumulation in virally infected cells makes this drug unique: DRDO
On May 1, DCGI has granted permission for Emergency Use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country: DRDO
